
Conference Coverage
about 1 month ago
Trade & Channel Strategies 2025: Waiting, Watching, and Reshoringabout 1 month ago
Trade & Channel Strategies 2025: Curatio's Priorities for Next Yearabout 1 month ago
Trade & Channel Strategies 2025: Inside the Push to Optimize GTNabout 1 month ago
Trade & Channel Strategies 2025: Inside Pharma’s Turning Pointabout 2 months ago
Trade & Channel Strategies 2025: Topics of Interestabout 2 months ago
The Future of Pharma LogisticsLatest Content

Why Trust Is the Biggest Barrier to Supply Chain Transparency

Morris & Dickson Acquires Prodigy Health to Expand Specialty and Plasma Distribution Capabilities

Pharma Pulse: Climate Risks to the Supply Chain

WISeR Spending or Unneeded delays in Healthcare? Prior Authorizations, AI in Medicare Prompt Concerns

Pharma Industry Uncertainty in Wake of On/Off Greenland Tariffs

Shorts










Podcasts
All News

In today’s Pharma Pulse, global pharmaceutical production hits a surge as manufacturers brace for US tariff shifts, while a new study reveals how smart speakers are slashing A1C levels for older adults.

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

In the second part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, describes how AI-driven orchestration, real-time data integration, and federated learning are reshaping pharmaceutical supply chains for faster, safer, and more agile operations.

In today’s Pharma Pulse, the United States finalizes its departure from global health oversight, while domestic providers face a record-breaking surge in respiratory hospitalizations.

The agency will evaluate FISP after early results show major gains in speed, capacity, and real-time risk mitigation across US ports of entry.

Artificial intelligence is helping pharma teams uncover critical safety signals faster, lower costs, and shift pharmacovigilance from compliance to competitive advantage.

In today’s Pharma Pulse, Congress races to secure funding, while Novavax nets a half-billion-dollar validation of its non-aluminum vaccine technology.

The France-based provider brings its cloud-native WMS and automation expertise to the US market.

In the final part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, explains how understanding premiums, coverage trade-offs, and HSAs remains a major challenge for patients—and for policymakers designing new plans.

In today’s Pharma Pulse, over 200 health groups denounce childhood vaccine schedule cuts, GSK acquires RAPT Therapeutics, and BD partners with ten23 health to scale large-volume injectors.

The partnership aims to speed commercialization, reduce risk, and enable large-volume biologics to shift from IV to subcutaneous delivery.

In the fourth part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, outlines the financial pressures that make sustained safety net protections a healthcare imperative.

In today’s Pharma Pulse, the FDA and EMA synchronize on AI standards, a potential divide in pricing strategy occurs, and BoomRx launches a needle-free nanoemulsion for weight loss.

The platform is helping to improve absorption, consistency, and scalable care delivery.

In the third part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, points out that from employer-paid premiums to Medicare and Medicaid subsidies, the US system relies on layered financial support to keep coverage within reach—underscoring how few individuals can realistically pay the full cost of care or insurance on their own.












